Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc (NASDAQ: BYSI) is a clinical-stage biopharmaceutical leader advancing innovative cancer therapies through its Plinabulin pipeline and target protein degradation research. This page serves as the definitive source for verified company updates, providing investors and researchers with essential insights into therapeutic developments and strategic initiatives.
Access timely announcements spanning clinical trial progress, regulatory milestones, and partnership agreements. Our curated collection includes press releases on Plinabulin's multifaceted mechanism of action, updates from global Phase 3 studies, and innovations from the SEED Therapeutics collaboration. Each update is vetted for accuracy to support informed decision-making.
Bookmark this resource for structured access to BeyondSpring's scientific advancements in immuno-oncology and protein degradation technology. Regular updates ensure you maintain current awareness of the company's progress in addressing unmet needs in NSCLC and other oncology indications.
BeyondSpring (NASDAQ: BYSI) has appointed Dr. Ravindra Majeti, Chief of Hematology at Stanford University, to its Board of Directors. Dr. Majeti co-founded Forty Seven, Inc., which was acquired by Gilead for $4.9 billion. His expertise in hematological cancers is expected to enhance the development of BeyondSpring's leading asset, Plinabulin, currently undergoing Phase 3 trials for chemotherapy-induced neutropenia and non-small cell lung cancer. The leadership change is anticipated to bolster the company's innovation and clinical outcomes.
BeyondSpring (NASDAQ: BYSI) has initiated an Expanded Access Program (EAP) for its late-stage asset, Plinabulin, aimed at preventing chemotherapy-induced neutropenia (CIN) in cancer patients during the COVID-19 pandemic. The first patient was enrolled on July 28, 2020, at Redlands Community Hospital, where the combination of Plinabulin and Pegfilgrastim effectively avoided Grade 4 neutropenia in the second cycle of chemotherapy. This program responds to updated NCCN guidelines to maximize protection for cancer patients while conserving healthcare resources.
BeyondSpring, a biopharmaceutical company focusing on innovative cancer therapies, announced the pricing of a public offering of 1,930,000 ordinary shares at $13.00 each, alongside a private placement of 384,615 shares to Decheng Capital. The total gross proceeds are projected to be approximately $30.1 million. Funds will support the commercialization of Plinabulin and further clinical development. The public offering is set to close on June 23, 2020, while the private placement is expected on July 2, 2020.
BeyondSpring Inc. (BYSI) announced a public offering of ordinary shares, expected to raise funds for the commercialization of its lead therapy, Plinabulin, and to support ongoing clinical development. The offering also includes a private placement with Decheng Capital. Jefferies and William Blair are acting as joint book-running managers. The offering is subject to market conditions and may not proceed as planned. BeyondSpring is focused on developing innovative immuno-oncology therapies, with Plinabulin currently in multiple Phase 3 clinical trials.
BeyondSpring (NASDAQ: BYSI) announced positive topline results from the PROTECTIVE-2 Phase 3 trial, evaluating Plinabulin in combination with Neulasta against Neulasta alone. The primary endpoint of reducing Grade 4 neutropenia was met (p<0.01), along with key secondary endpoints for the duration of severe neutropenia (p<0.05). The trial showed that the combination offers early protection during the first chemotherapy cycle, potentially addressing a significant unmet medical need in cancer care. A conference call will provide further insights.
BeyondSpring (NASDAQ: BYSI) announced promising results from the PROTECTIVE-2 Phase 2 trial, showcasing its lead asset Plinabulin in combination with Neulasta. The study revealed a 72% reduction in chemotherapy dose adjustments, with only 6.3% of patients needing dose reduction compared to 22.7% in the Neulasta-only group. Additionally, no patients downgraded their chemotherapy regimen in the Plinabulin group, potentially leading to better long-term survival outcomes. The improvements address the critical issue of Grade 4 neutropenia prevalent during high-risk chemotherapy.
BeyondSpring (NASDAQ: BYSI) announced that its Phase 3 Dublin-3 clinical trial for Plinabulin in non-small cell lung cancer (NSCLC) has received a favorable recommendation from the Data & Safety Monitoring Board (DSMB) after reviewing data from over 500 patients. The trial aims to evaluate the efficacy of Plinabulin combined with docetaxel compared to docetaxel alone in second- and third-line EGFR wild-type NSCLC patients. Previous Phase 2 results showed that this combination significantly extends overall survival while reducing severe neutropenia rates.
FAQ
What is the current stock price of Beyondspring (BYSI)?
What is the market cap of Beyondspring (BYSI)?
